Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by bull8888on Feb 24, 2006 2:47pm

244 Views

Post# 10422907

RE: What is the market saying??????

"Heading south so there will be lots of "cheap" shares available, including mine.- BBClobber Feb 23/06 BB, I am a liitle confused why you would still care since you have sold your shares? Good on you for getting out at a price you were comfortable at. For those that truly understand the magnitude of Revas, this is just the beginning. These bios always take longer to deliver than promised. Part of the game when dealing with the big boys. Good luck with your next investment.

Bullboard Posts

AtkinsRéalis supports Poland’s nuclear power endeavour